Brief: Bellus Health Initiates Phase 1 Clinical Study For Its Chronic Cough Drug Candidate, BLU-5937
09/07/2018 12:34
July 9 (Reuters) - BELLUS Health Inc BLU.TO :
* BELLUS HEALTH INITIATES PHASE 1 CLINICAL STUDY FOR ITS
CHRONIC
COUGH DRUG CANDIDATE, BLU-5937
* BELLUS HEALTH INC - STUDY RESULTS PHASE 1 CLINICAL STUDY
FOR
BLU-5937EXPECTED IN Q4 OF 2018
* BELLUS HEALTH INC - PHASE 2 PROOF-OF-CONCEPT STUDY FOR
BLU-5937
IS EXPECTED TO BE INITIATED IN 2019
Source text for Eikon: ID:nCNWJF64La
Further company coverage: BLU.TO
((Reuters.Briefs@thomsonreuters.com;))
Recent news on BELLUS Health
See all newsBrief: Bellus Health Inc. Calls Special Shareholders’ Meeting In Connection With Gsk Acquisition
Brief: Bellus Health Reports First Quarter 2023 Financial Results And Business Highlights
Press Digest: British Business - April 19
Canada Stocks: Toronto market extends winning streak on 'soft landing' hopes
Bellus soars as GSK plans to buy drug developer for $2 bln